Take2 Prophecy™ is Now Serving More than 20,000 Employees Upon Launching on HSBC Life Benefits+
Since March 2021, the Take2 Prophecy™ Test for Nasopharyngeal Cancer (“the Test”) and related health assessment services are available on HSBC Life Benefits+ as one of the new employee benefits. At present, all employees of HSBC, Hang Seng Bank and other subsidiaries of the HSBC Group can access the Test with a special offer on their one-stop group medical benefits platform.
Take2 Health is excited to team up with respectable corporations to raise the awareness of early cancer detection in the local communities. The Test has received noticeable attention from users during the initial phase of the launch, showing the public’s demand for early cancer detection services. Take2 Health will continue devoting its dedication to providing early cancer detection services with varieties, aiming to bring benefit to the public.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)